explore -WSS

explore

author：focus 2025-10-03 00:40:05 - browse：95293

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： TB outbreak tied to bone grafts underscores testing shortcomings

WSS

TB outbreak tied to bone grafts underscores testing shortcomings

Rise in cancer among younger people worries and puzzles doctors

What causes rare myocarditis in young men after Covid vaccines?

What to watch for from Zogenix and Amicus clinical trials

Will the FTC rein in IQVIA's health data empire?

In the gardens at Boston Children's Hospital, families find sanctuary

explore

explore

explore

How one medical school became remarkably diverse

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Drug repurposing or repositioning? The language matters

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

After affirmative action ruling, medical educators look to 'holistic review'

TB outbreak tied to bone grafts underscores testing shortcomings

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

GOP presidential candidates start declaring their loyalty

How to save PrEP access — and even expand it

Kim Kardashian sparks debate on benefits of full

hotspot

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Target recalls 2.2 million additional candles due to laceration, burn hazards

UHS says company favors patients whose insurance pays more

Former reverend arrested for allegedly killing 8

Novo acquires Inversago for up to $1 billion

Why patients can’t get everything they want on drug pricing

explore

hotspot

explore

leisure time